New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-HK$11m). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (182% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (HK$735.2m market cap, or US$93.9m). New Risk • Mar 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$762.9m (US$97.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-HK$11m). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (182% increase in shares outstanding). Minor Risk Market cap is less than US$100m (HK$762.9m market cap, or US$97.4m). New Risk • Mar 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-HK$11m). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (182% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change). Annonce • Feb 02
China Health Group Limited has filed a Follow-on Equity Offering in the amount of HKD 25.44 million. China Health Group Limited has filed a Follow-on Equity Offering in the amount of HKD 25.44 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 48,000,000
Price\Range: HKD 0.53
Transaction Features: Subsequent Direct Listing Reported Earnings • Nov 30
First half 2026 earnings released: HK$0.021 loss per share (vs HK$0.036 loss in 1H 2025) First half 2026 results: HK$0.021 loss per share (improved from HK$0.036 loss in 1H 2025). Revenue: HK$19.6m (up 5.0% from 1H 2025). Net loss: HK$10.4m (loss narrowed 40% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. New Risk • Nov 29
New major risk - Negative shareholders equity The company has negative equity. Total equity: -HK$11m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-HK$11m). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (172% increase in shares outstanding). Minor Risk Significant insider selling over the past 3 months (HK$4.1m sold). Annonce • Nov 18
China Health Group Limited to Report First Half, 2026 Results on Nov 28, 2025 China Health Group Limited announced that they will report first half, 2026 results on Nov 28, 2025 New Risk • Oct 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 172% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (172% increase in shares outstanding). Minor Risk Market cap is less than US$100m (HK$642.8m market cap, or US$82.6m). Annonce • Oct 07
China Health Group Limited has completed a Follow-on Equity Offering in the amount of HKD 84.749343 million. China Health Group Limited has completed a Follow-on Equity Offering in the amount of HKD 84.749343 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 119,689,791
Price\Range: HKD 0.1
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 700,000,000
Price\Range: HKD 0.1
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,803,637
Price\Range: HKD 0.1
Transaction Features: Rights Offering; Subsequent Direct Listing New Risk • Aug 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 30% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 20% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (30% increase in shares outstanding). Revenue is less than US$5m (HK$39m revenue, or US$5.0m). Market cap is less than US$100m (HK$434.6m market cap, or US$55.6m). Annonce • Jul 25
China Health Group Limited, Annual General Meeting, Sep 26, 2025 China Health Group Limited, Annual General Meeting, Sep 26, 2025, at 11:00 China Standard Time. Location: unit 801, 8/f., china insurance group building, 141 des voeux road central., Hong Kong Reported Earnings • Jul 07
Full year 2025 earnings released: HK$0.14 loss per share (vs HK$0.085 loss in FY 2024) Full year 2025 results: HK$0.14 loss per share (further deteriorated from HK$0.085 loss in FY 2024). Revenue: HK$38.9m (down 35% from FY 2024). Net loss: HK$67.8m (loss widened 69% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Annonce • Jun 18
China Health Group Limited to Report Fiscal Year 2025 Results on Jun 30, 2025 China Health Group Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Jun 30, 2025 Annonce • May 23
China Health Group Limited has filed a Follow-on Equity Offering in the amount of HKD 14.984843 million. China Health Group Limited has filed a Follow-on Equity Offering in the amount of HKD 14.984843 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 149,848,428
Price\Range: HKD 0.1
Transaction Features: Rights Offering Board Change • May 23
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Non-Executive Director Huimin Yang was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. New Risk • Apr 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: HK$71.3m (US$9.19m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-HK$3.7m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (HK$71.3m market cap, or US$9.19m). Reported Earnings • Jan 04
First half 2025 earnings released: HK$0.036 loss per share (vs HK$0.032 loss in 1H 2024) First half 2025 results: HK$0.036 loss per share (further deteriorated from HK$0.032 loss in 1H 2024). Revenue: HK$18.7m (down 34% from 1H 2024). Net loss: HK$17.4m (loss widened 16% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Annonce • Dec 30
China Health Group Limited Appoints Yang Huimin as Independent Non-Executive Director and Committee's The board of directors of China Health Group Limited announce that Ms. Yang Huimin (‘Ms. Yang’) has been appointed as an independent non-executive Director and members of the audit committee, remuneration committee and nomination committee of the Company with effect from 30 December 2024. Ms. Yang Huimin, aged 48, obtained a bachelor's degree in economics from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) in 1998 and a Master's degree of Management in Nanjing University in 2001. Ms. Yang is a non-practising member of the Chinese Institute of Certified Public Accountants (CPA) and holds the Chartered Financial Analyst qualification (CFA). Ms. Yang has extensive experience in company finance and listed company operations. In 2010 - 2014, she joined COFCO Property (Group) Co. Ltd. (a company listed on the Shenzhen Stock Exchange with stock code of SZ000031) and successively became the vice general manager of the financial department, the general manager of the operation department and the vice general manager of the Shenzhen Centre City Company. In 2014 - 2015, Ms. Yang was appointed as the chief financial officer and secretary of the board of directors of COFCO & CM (Shenzhen) Grain Electronic Trading Centre Co. Ltd. She was appointed as an independent non-executive director of the Company on 18 June 2016 and resigned on 7 May 2018. Reported Earnings • Dec 01
First half 2025 earnings released: HK$0.035 loss per share (vs HK$0.032 loss in 1H 2024) First half 2025 results: HK$0.035 loss per share (further deteriorated from HK$0.032 loss in 1H 2024). Revenue: HK$18.7m (down 38% from 1H 2024). Net loss: HK$17.4m (loss widened 16% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. New Risk • Nov 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -HK$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-HK$3.7m free cash flow). Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (HK$299.9m market cap, or US$38.5m). Annonce • Nov 19
China Health Group Limited to Report First Half, 2025 Results on Nov 29, 2024 China Health Group Limited announced that they will report first half, 2025 results on Nov 29, 2024 New Risk • Nov 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Market cap is less than US$100m (HK$339.2m market cap, or US$43.6m). New Risk • Sep 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Market cap is less than US$100m (HK$378.6m market cap, or US$48.6m). Recent Insider Transactions • Aug 24
Non-Executive Director recently bought HK$291k worth of stock On the 16th of August, Jingming Wang bought around 510k shares on-market at roughly HK$0.57 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Annonce • Aug 23
China Health Group Limited Announces Redesignation of Xing Yong from A Non- Executive Director to an Executive Director China Health Group Limited announces that Mr. Xing Yong has been re-designated from a non- executive Director to an executive Director of the Company effective from 22 August 2024. Mr. Xing Yong, aged 59, a senior engineer, was appointed as the non-executive Director on 18 June 2016. He graduated from Huaqiao University majoring in mechanical manufacturing. In 2004, Mr. Xing formed a Hong Kong company conducting the business of trading and shipping agency for customers from the United States, Europe and South Africa. Mr. Xing was appointed as the deputy general manager of Shenzhen Teamrun Investment Development Company Limited since 2015 and oversees commercial real estate development projects. Save as disclosed above, he has not held any other directorship in listed companies in the last three years. Reported Earnings • Aug 05
Full year 2024 earnings released: HK$0.085 loss per share (vs HK$0.099 loss in FY 2023) Full year 2024 results: HK$0.085 loss per share (improved from HK$0.099 loss in FY 2023). Revenue: HK$59.9m (down 22% from FY 2023). Net loss: HK$40.2m (loss narrowed 4.4% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Annonce • Jul 31
China Health Group Limited, Annual General Meeting, Sep 12, 2024 China Health Group Limited, Annual General Meeting, Sep 12, 2024, at 11:00 China Standard Time. Location: floor 12 conference room, block b, building 11, shenzhen bay eco technology park, no. 16 keji south road, yuehai sub-district, nanshan district, shenzhen China New Risk • Jul 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.4% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Significant insider selling over the past 3 months (HK$10m sold). Market cap is less than US$100m (HK$393.3m market cap, or US$50.4m). Reported Earnings • Jun 28
Full year 2024 earnings released: HK$0.084 loss per share (vs HK$0.099 loss in FY 2023) Full year 2024 results: HK$0.084 loss per share (improved from HK$0.099 loss in FY 2023). Revenue: HK$59.9m (down 22% from FY 2023). Net loss: HK$40.2m (loss narrowed 4.4% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Annonce • Jun 18
China Health Group Limited to Report Fiscal Year 2024 Results on Jun 27, 2024 China Health Group Limited announced that they will report fiscal year 2024 results on Jun 27, 2024 Reported Earnings • Dec 02
First half 2024 earnings released: HK$0.032 loss per share (vs HK$0.066 loss in 1H 2023) First half 2024 results: HK$0.032 loss per share (improved from HK$0.066 loss in 1H 2023). Revenue: HK$30.3m (down 6.1% from 1H 2023). Net loss: HK$15.1m (loss narrowed 46% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings. New Risk • Dec 01
New major risk - Revenue and earnings growth Earnings have declined by 4.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-HK$19m free cash flow). Earnings have declined by 4.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Market cap is less than US$100m (HK$537.8m market cap, or US$68.8m). Annonce • Nov 21
China Health Group Limited to Report First Half, 2024 Results on Nov 30, 2023 China Health Group Limited announced that they will report first half, 2024 results on Nov 30, 2023 New Risk • Aug 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-HK$9.6m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Significant insider selling over the past 3 months (HK$6.3m sold). Market cap is less than US$100m (HK$391.6m market cap, or US$50.1m). Annonce • Aug 03
China Health Group Limited, Annual General Meeting, Sep 18, 2023 China Health Group Limited, Annual General Meeting, Sep 18, 2023, at 11:00 China Standard Time. Agenda: To consider capital reduction. Reported Earnings • Aug 02
Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022) Full year 2023 results: HK$0.099 loss per share (further deteriorated from HK$0.03 loss in FY 2022). Revenue: HK$76.4m (down 29% from FY 2022). Net loss: HK$42.0m (loss widened 244% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. New Risk • Jul 25
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: HK$6.3m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Significant insider selling over the past 3 months (HK$6.3m sold). Market cap is less than US$100m (HK$339.7m market cap, or US$43.5m). Reported Earnings • Jul 01
Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022) Full year 2023 results: HK$0.099 loss per share (further deteriorated from HK$0.03 loss in FY 2022). Revenue: HK$76.4m (down 29% from FY 2022). Net loss: HK$42.0m (loss widened 244% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings. Annonce • Jun 17
China Health Group Limited to Report Fiscal Year 2023 Results on Jun 30, 2023 China Health Group Limited announced that they will report fiscal year 2023 results on Jun 30, 2023 Recent Insider Transactions • Apr 23
Executive Chairman recently bought HK$932k worth of stock On the 17th of April, Fan Zhang bought around 786k shares on-market at roughly HK$1.19 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Fan's only on-market trade for the last 12 months. Reported Earnings • Jan 01
First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022) First half 2023 results: HK$0.066 loss per share (further deteriorated from HK$0.013 loss in 1H 2022). Revenue: HK$32.3m (down 23% from 1H 2022). Net loss: HK$27.6m (loss widened 430% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 01
First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022) First half 2023 results: HK$0.066 loss per share (further deteriorated from HK$0.013 loss in 1H 2022). Revenue: HK$32.3m (down 23% from 1H 2022). Net loss: HK$27.6m (loss widened 430% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. 3 independent directors (5 non-independent directors). Non-Executive Director Yong Xing was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 05
Full year 2022 earnings released: HK$0.003 loss per share (vs HK$0.002 loss in FY 2021) Full year 2022 results: HK$0.003 loss per share (down from HK$0.002 loss in FY 2021). Revenue: HK$107.0m (up 22% from FY 2021). Net loss: HK$12.2m (loss widened 58% from FY 2021). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 02
Full year 2022 earnings released Full year 2022 results: Revenue: HK$107.0m (up 22% from FY 2021). Net loss: HK$12.2m (loss widened 58% from FY 2021). Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. 3 independent directors (5 non-independent directors). Non-Executive Director Yong Xing was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Jan 01
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: HK$0.001 loss per share (vs HK$0.001 loss in 1H 2021). Revenue: HK$42.0m (up 26% from 1H 2021). Net loss: HK$5.21m (loss widened 30% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 02
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: HK$0.001 loss per share (vs HK$0.001 loss in 1H 2021). Revenue: HK$42.0m (up 26% from 1H 2021). Net loss: HK$5.21m (loss widened 30% from 1H 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 03
Full year 2021 earnings released: HK$0.002 loss per share (vs HK$0.009 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: HK$87.9m (up 95% from FY 2020). Net loss: HK$7.74m (loss narrowed 79% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Executive Departure • Mar 10
No-Executive Director has left the company On the 8th of March, Yu Weng's tenure as No-Executive Director ended after 4.7 years in the role. We don't have any record of a personal shareholding under Yu's name. A total of 3 executives have left over the last 12 months. Reported Earnings • Dec 25
First half 2021 earnings released: HK$0.001 loss per share The company reported a solid first half result with improved revenues and control over expenses, though losses increased. First half 2021 results: Revenue: HK$33.4m (up 60% from 1H 2020). Net loss: HK$4.00m (loss widened 54% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 04
First half 2021 earnings released: HK$0.001 loss per share The company reported a solid first half result with improved revenues and control over expenses, though losses increased. First half 2021 results: Revenue: HK$33.4m (up 60% from 1H 2020). Net loss: HK$4.00m (loss widened 54% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.